Sander Tuit

Sander Tuit

Auto-generated profile, based on publicly available information

Sander Tuit

Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2016 in OncoImmunology
Verified
Journal Article
Open access
RARob J.W. Arts
Rob J.W. Arts
TPTheo Plantinga
Theo Plantinga
STSander Tuit
Sander Tuit
TUThomas Ulas
Thomas Ulas
BHBas Heinhuis
Bas Heinhuis
RNRomana Netea-Maier
Romana Netea-Maier
Tumor-associated macrophages (TAMs) are key components of the tumor microenvironment in non-medullary thyroid cancer (TC), the most common endocrine malignancy. However, little is known regarding the regulation of their function in TC. Transcriptome analysis in a model of TC-induced macrophages identified increased inflammatory characteristics and rewiring of cell metabolism as key functional changes. This functional reprogramming was partly mediated by TC-derived lactate that induced upregulation of cytokine production through an AKT1/mTOR-dependent increase in aerobic glycolysis. This led to epigenetic modifications at the level of histone methylation, and subsequently long-term functional changes. Immunohistochemistry assessment validated the increase in glycolysis enzymes and lactate receptor in TAMs in tissue samples from patients with TC. In conclusion, Akt/mTOR-dependent glycolysis mediates TC-induced reprogramming of TAMs and inflammation, and this may represent a novel therapeutic target in TC.

16 March 2023 in Blood
Verified
Journal Article
Open access
PDF file
AHAstrid G.S. van Halteren
Astrid G.S. van Halteren
JSJessica S. Suwandi
Jessica S. Suwandi
STSander Tuit
Sander Tuit
JBJelske Borst
Jelske Borst
SLSandra Laban
Sandra Laban
WFWillem E. Fibbe
Willem E. Fibbe
Acute graft-versus-host disease (aGVHD) is an immune cell‒driven, potentially lethal complication of allogeneic hematopoietic stem cell transplantation affecting diverse organs, including the skin, liver, and gastrointestinal (GI) tract. We applied mass cytometry (CyTOF) to dissect circulating myeloid and lymphoid cells in children with severe (grade III-IV) aGVHD treated with immune suppressive drugs alone (first-line therapy) or in combination with mesenchymal stromal cells (MSCs; second-line therapy). These results were compared with CyTOF data generated in children who underwent transplantation with no aGVHD or age-matched healthy control participants. Onset of aGVHD was associated with the appearance of CD11b+CD163+ myeloid cells in the blood and accumulation in the skin and GI tract. Distinct T-cell populations, including TCRγδ+ cells, expressing activation markers and chemokine receptors guiding homing to the skin and GI tract were found in the same blood samples. CXCR3+ T cells released inflammation-promoting factors after overnight stimulation. These results indicate that lymphoid and myeloid compartments are triggered at aGVHD onset. Immunoglobulin M (IgM) presumably class switched, plasmablasts, and 2 distinct CD11b– dendritic cell subsets were other prominent immune populations found early during the course of aGVHD in patients refractory to both first- and second-line (MSC-based) therapy. In these nonresponding patients, effector and regulatory T cells with skin- or gut-homing receptors also remained proportionally high over time, whereas their frequencies declined in therapy responders. Our results underscore the additive value of high-dimensional immune cell profiling for clinical response evaluation, which may assist timely decision-making in the management of severe aGVHD.

26 June 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
RARosa A. van Amerongen
Rosa A. van Amerongen
STSander Tuit
Sander Tuit
DRDennis F.G. Remst
Dennis F.G. Remst
AWAnne K. Wouters
Anne K. Wouters
SSSterre L. Siekman
Sterre L. Siekman
MHMirjam H.M. Heemskerk
Mirjam H.M. Heemskerk
The efficacy of most immunotherapies for prostate cancer is limited by poor tumor immunogenicity as evidenced by minimal T-cell infiltration. Treatment with T cells engineered to express T-cell receptors (TCR) targeting prostate-specific antigens offers a potential solution by bypassing endogenous T-cell repertoire limitations. Through differential gene expression analysis, we have identified kallikrein-related peptidases 2, 3, and 4 (KLK2, KLK3, and KLK4) and homeobox B13 (HOXB13) as strictly prostate lineage–specific genes with high expression in prostate cancer and no expression in healthy tissues of risk. Naturally processed peptides derived from these antigens were identified, enabling T-cell enrichment using peptide–MHC multimers. High-avidity T cells targeting these antigens were isolated from allogeneic HLA-mismatched donors. After screening for on-target tumor specificity and absence of off-target reactivity, TCRs recognizing KLK4 in HLA-A*02:01 and KLK3 in HLA-B*35:01 were sequenced and further tested. TCRs were expressed in T cells through TCR gene transfer and TCRs with best performance were selected. Using combinatorial peptide library scanning, the cross-reactive potential of the KLK4-A2 and KLK3-B35 TCRs was analyzed. The KLK3-B35 TCR exhibited cross-reactivity against two additional peptides derived from LOXHD1 and CDH23, with broad tissue expression, and was therefore excluded. The KLK4-A2 TCR was highly specific for the KLK4 peptide. Further testing confirmed effective cytotoxic killing potential of KLK4-A2 TCR in vitro and in vivo, underscoring its therapeutic potential. These findings highlight the promise of the KLK4-A2 TCR for prostate cancer immunotherapy and demonstrate that prostate-specific antigens can be effectively targeted using TCR gene transfer strategies.

1 August 2025
Verified
Other
Open access
PDF file
RARosa A. van Amerongen
Rosa A. van Amerongen
STSander Tuit
Sander Tuit
DRDennis F.G. Remst
Dennis F.G. Remst
AWAnne K. Wouters
Anne K. Wouters
SSSterre L. Siekman
Sterre L. Siekman
MHMirjam H.M. Heemskerk
Mirjam H.M. Heemskerk
IFN-ƴ production (ng/mL) of the TCR-T cells cocultured overnight with peptide-loaded (500 nM) prostate tumor cell lines (E:T=1:6). (A) KLK4-A2 (23.1A6) TCR-T cells and CMV TCR-T cells stimulated with HLA-A2+ prostate tumor cell lines, (B) KLK3-B35 (36.2.2E3) TCR-T cells and CMV TCR-T cells stimulated with HLA-B35+ prostate tumor cell lines. Bars represent mean and symbols depict averaged duplicate values from two different donors. Experiments were performed simultaneously with the experiments shown in Figure 4B, and symbols of the two donors match. (E:T: effector:target ratio)

1 August 2025
Verified
Other
Open access
RARosa A. van Amerongen
Rosa A. van Amerongen
STSander Tuit
Sander Tuit
DRDennis F.G. Remst
Dennis F.G. Remst
AWAnne K. Wouters
Anne K. Wouters
SSSterre L. Siekman
Sterre L. Siekman
MHMirjam H.M. Heemskerk
Mirjam H.M. Heemskerk
Supplementary Table S2 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer

1 August 2025
Verified
Other
Open access
PDF file
RARosa A. van Amerongen
Rosa A. van Amerongen
STSander Tuit
Sander Tuit
DRDennis F.G. Remst
Dennis F.G. Remst
AWAnne K. Wouters
Anne K. Wouters
SSSterre L. Siekman
Sterre L. Siekman
MHMirjam H.M. Heemskerk
Mirjam H.M. Heemskerk
IFN-ƴ production (ng/mL) of T cell clones 23.1A6 (KLK4-A2), 40.1.A8 (KLK4-A2), 41.1H9 (KLK4-A2), 36.2.2E3 (KLK3-B35) and 29.1.1C12 (KLK3-B35) after overnight coculture with 25 different EBV-LCLs, expressing all HLA alleles with an allele frequency > 1% present in the Caucasian population (E:T=1:6). Bars represent mean and SD of technical duplicates. (EBV-LCL: Epstein-Barr virus transformed lymphoblastoid cell lines, E:T: effector:target ratio)